8-K - HeartSciences Inc. (0001468492) (Filer)
8-K/A - HeartSciences Inc. (0001468492) (Filer)
8-K - Heart Test Laboratories, Inc. (0001468492) (Filer)
S-1/A - Heart Test Laboratories, Inc. (0001468492) (Filer)
DEFA14A - Heart Test Laboratories, Inc. (0001468492) (Filer)
DEF 14A - Heart Test Laboratories, Inc. (0001468492) (Filer)
8-K - Heart Test Laboratories, Inc. (0001468492) (Filer)
10-Q - Heart Test Laboratories, Inc. (0001468492) (Filer)
8-K - Heart Test Laboratories, Inc. (0001468492) (Filer)
8-K - Heart Test Laboratories, Inc. (0001468492) (Filer)
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm
Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024. Mr. Simpson is scheduled to participate in a fireside chat with analyst Allen Klee at 10:30 a.m. Eastern Time on Thursday, October 17th.
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update. First Fiscal Quarter 2025 Highlights: During the first quarter of fiscal year 2025 ("Q1 FY2025"), HeartSciences has seen material progress for both its MyoVista wavECGTM device, MyoVista InsightsTM cloud-platform and associated first cl
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds. The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025. Andrew Simpson, CEO of HeartSciences, said, "We have extended our capital runway by $2.4 million since late August ahead of our upcoming FDA subm
Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the fiscal year 2024 ended April 30, 2024 and provided a business update. Fiscal Year 2024 and subsequent update: The Company saw a number of major positive developments and resolved several significant challenges. Strategic HeartSciences has fundamentally expanded and changed its business in the period and we believ
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced an analysis published by the Innovation Value Institute (IVI) titled "Introduction of AI assisted Digital Health Technology to Improve Cardiovascular Pathway Efficiency" focused on the MyoVista® wavECG™'s potential to radically improve the cardiovascular pathway efficiency. Founded in 2006, the Maynooth University, Ireland based IVI is a multidisciplinary re
Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the MyoVista® wavECGTM has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024. Founded in 2
Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that intellectual property (IP) exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for the detection of left ventricular (LV) and/or right ventricular (RV) dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio. Heart failure (HF) is
Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that on June 3, 2024, the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements and the schedul
Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European ma
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
4 - Heart Test Laboratories, Inc. (0001468492) (Issuer)
Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host
Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has
Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi
Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board. "We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences' Scientific Advisory Board," said Andrew Simpson, CEO
Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has signed a distribution agreement with FJ Medical, Denmark. FJ Medical has been appointed as HeartSciences' distributor for the MyoVista® wavECGTM and related supplies for the Nordic countries of Denmark, Sweden, Norway and Finland. FJ Medical has more than 23 years of experience selling cardiac imaging and screening equipment in the Nordic region and i
Southlake, Texas, July 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023. Key milestones during Fiscal 2023 and to date: Completed patient enrollment for the MyoVista® wavECGTM multi-center pivotal study; on track for FDA submission later in the year;Further expansion of the IP portfolio in the US and internationally, bringing the total number
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million. Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million. I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million. Agenus (NASDAQ:AGEN) stock
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million. Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million. Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million. Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards b
https://data.epo.org/publication-server/publications/pdf?path=2024/21/DOC/EPNWB1/EP20193719NWB1/EP20193719NWB1.pdf
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO).To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands.
Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) fell sharply during Friday's session after the company reduced its dividend and said it expects third-quarter and fourth-quarter results below its prior expectations. Cracker Barrel Old Country Store shares dipped 14.4% to $49.01 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Fangdd Network Group Ltd. (NASDAQ:DUO) shares jumped 258.6% to $1.4709. FangDD filed 2023 annual report on Form 20-F. Akanda Corp. (NASDAQ:AKAN) jumped 129.4% to $0.3053 after jumping around 27% on Thursday. Crown ElectroKinetics Corp (NASDAQ:CRKN) shares jumped 89.6% to $0.4580. The stock has seen interes
- SEC Filing